KRAS and cholangiocarcinoma: Mutations in FGFR2 have been detected in 5.6% [22] and FGFR2 and KRAS mutations in 5% in the present study of ctDNA samples from cholangiocarcinoma patients, with other targetable aberrations identified in <6% to 44% of cholangiocarcinoma patients [15].